학술논문

Fabry disease: the importance of the enzyme replacement therapy (TRE), treating quickly and efficiently
Document Type
article
Source
Revista de Nefrología, Diálisis y Trasplante, Vol 34, Iss 2, Pp 82-86 (2014)
Subject
enfermedad de Fabry
terapia reemplazo enzimático
Agalsidasa Beta
podocito
lisosoma
dolor neuropático
Medicine
Specialties of internal medicine
RC581-951
Language
Spanish; Castilian
ISSN
0326-3428
2346-8548
Abstract
Fabry Disease is a lysosomal disorder due to the absence or deficiency of the Alpha galactosidase A enzyme that causes a pathological accumulation of glycosphingolipids mainly in the endothelial cells, vascular smooth muscle cells and podocytes among others. Enzyme replacement therapy is the only option for a specific treatment at present. Increasing knowledge of the physiopathological mechanisms has changed the management of the disease and above all, when treatment should begin. At present, beginning treatment at an early age seems to be a way of preventing and in some cases reverting some of the signs and symptoms of Fabry disease.